Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


We Haven’t Ruled Out Drug Price Increases, Says Regeneron’s Schleifer

Executive Summary

In an exclusive interview, one of the most direct CEOs in the industry, Regeneron’s Len Schleifer, clarifies his attitude to drug pricing and growing internal innovation.


Related Content

US Drug Pricing Challenges Poised To Impact Pharma Growth, Leerink Warns
Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer
Regeneron And Bluebird Team Up In Cell Therapy "Joint Venture"-Style Deal
Praluent Pricing: Collaboration With ICER Sets A New Standard
Sanofi, Regeneron Setting 'New Paradigm' With Dupixent Pricing In US?
Pharma CEOs Tackle A Tough Question: “Why Don’t People Like You?”


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts